Kyle Doherty

Kyle Doherty joined MJH Life Sciences in 2021 and is the lead editor for Oncology Fellows. He also produces print content for OncologyLive, as well as news and conference updates for OncLive.com. Email: kdoherty@mjhlifesciences.com

Articles

Zanubrutinib Demonstrates Long-Term Efficacy, Safety in Relapsed/Refractory CLL/SLL

December 7th 2025

Zanubrutinib displayed long-term PFS and responses in patients with relapsed/refractory CLL/SLL.

Real-World Data Suggest ctDNA Status More Accurately Captures EFS Outcomes Than PET-CT

December 6th 2025

ctDNA at end of treatment strongly predicted outcomes across lymphoma subtypes, outperforming imaging and supporting its role in personalized disease monitoring.

Zanubrutinib Plus R-CHOP Is Active in Untreated DLBCL With Specific Gene Expression

December 6th 2025

Zanubrutinib plus R-CHOP produced a high ORR and CR rate in untreated DLBCL with certain gene expression.

Adjuvant Atezolizumab Generates DFS, OS Benefit Regardless of Tumor Size, Nodal Status, and Prior NAC in ctDNA+ MIBC

December 6th 2025

Findings from an exploratory analysis of IMvigor011 support the use of serial ctDNA testing to guide atezolizumab use in MIBC.

Intravesical Cretostimogene Grenadenorepvec Is Active in BCG-Naive High-Risk NMIBC

December 6th 2025

Intravesical cretostimogene grenadenorepvec was efficacious and safe in high-risk BCG-naive non–muscle-invasive bladder cancer.

Management of Peripheral Neuropathy Does Not Compromise Survival Benefit With Frontline Enfortumab Vedotin/Pembrolizumab in Urothelial Cancer

December 5th 2025

Peripheral neuropathy was linked with improved efficacy outcomes after treatment with first-line enfortumab vedotin plus pembrolizumab in urothelial carcinoma.

Dr Desai on Future Research Directions in MPN and Other Hematologic Malignancies

December 5th 2025

Ruchi J. Desai, MD, discusses future research directions in MPN and other hematologic malignancies.

Belzutifan Maintains High, Durable Responses in VHL Disease–Associated Neoplasms At 5 Years

December 5th 2025

At 48 months, the majority of patients with VHL disease–associated tumors remained in response following treatment with belzutifan.

All Eyes Are on Novel Combination Therapies and Molecular Targets in MPN at ASH 2025

December 5th 2025

Ahead of the 2025 ASH Annual Meeting, experts in myeloproliferative neoplasms share the most anticipated research being presented during the meeting.

Inside the Most Anticipated CLL Abstracts: What to Expect From ASH 2025

December 5th 2025

Ahead of the 2025 ASH Annual Meeting, OncLive spoke with experts in CLL care to preview the most anticipated meeting abstracts.

Dr Smith on the Role of Radioligand Therapy in Prostate Cancer

December 4th 2025

Matthew R. Smith, MD, PhD, discusses how radioligand therapies are altering the prostate cancer treatment paradigm.

Relief of Venous Congestion May Improve Renal Preservation Despite Worse Baseline Function in RCC With IVC Thrombosis

December 4th 2025

Data from a comparative cohort study suggest that venous congestion is a modifiable driver of renal dysfunction in patients with RCC and IVC thrombosis.

Dr Randall on the Multidisciplinary Foundation of Research Into Sarcoma Survivorship

December 4th 2025

R. Lor Randall, MD, FACS, discusses the multidisciplinary nature of research aiming to develop a predictive model of sarcoma survivorship.

Gemcitabine Intravesical System Use Is Practical and Straightforward in NMIBC

December 4th 2025

Health care providers and allied health care professionals found the gemcitabine intravesical system straightforward to use and safe in NMIBC.

PLN-101095 Plus Pembrolizumab Displays Activity in ICI-Refractory Advanced Solid Tumors

December 4th 2025

PLN-101095 in combination with pembrolizumab led to responses in patients with ICI-refractory advanced solid tumors.

Loncastuximab Tesirine Plus Glofitamab Yields High CR Rates in DLBCL in Updated LOTIS-7 Analysis

December 4th 2025

Adding loncastuximab tesirine to glofitamab led to activity irrespective of disease status in relapsed/refractory diffuse large B-cell lymphoma.

Dr Gonzalez-Martin on the Efficacy of TUB-040 in Ovarian Cancer

December 3rd 2025

Antonio Gonzalez-Martin, MD, discusses the key efficacy findings from the NAPISTAR1-01 trial of TUB-040 in ovarian cancer.

Dr Bellmunt on Future Directions With ctDNA-Guided Immunotherapy in Urothelial Cancer

December 3rd 2025

Joaquim Bellmunt, MD, PhD, discusses future research directions with ctDNA-guided immunotherapy in urothelial cancer.

Dr Jänne on the Design of the FLAURA2 Trial of Osimertinib Plus Chemotherapy in EGFR+ NSCLC

December 3rd 2025

Pasi A. Jänne, MD, PhD, discusses the design of the FLAURA2 trial in EGFR+ NSCLC.

Maintenance Fuzuloparib Displays PFS Benefit in Newly Diagnosed, Advanced Ovarian Cancer

December 3rd 2025

Fuzuloparib extended PFS vs placebo regardless of the addition of apatinib in newly diagnosed advanced ovarian cancer.